Author: Editor

Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the next steps for the ongoing trial once they receive FDA approval and provides insight into the lighthouse clinical trial. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides answers where does melphalan flufenamide fit in the mix of RRMM treatment if broad-spectrum agents dominate? ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an…

OneOncology, the national association of independent group oncologists, said today that enrolling patients at their affiliate practices in clinical trials has increased marginally in March and April, just as the COVID-19 pandemic struck our communities hardest.  Clinical trial accruals occurred at a steady to slightly higher pace at OneOncology partner practices in March and April, while news outlets reported hundreds of clinical trials across the country have been suspended since March 1 due to the outbreak, especially in hospital-based settings that are disproportionately affected by the pandemics. “Elective medical procedures have stopped, but caring for cancer patients isn’t elective,” said…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses results of the HORIZON phase 2 data in RRMM. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an update on the final study results…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the combination of the pivotal phase 2 study, HORIZON and phase 3 study, OCEAN, becoming key studies for melphalan flufenamide in the US and the EU. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the significance of the latest data findings from the O-12-M1 clinical trial recently published. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an update…

Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the 5 clinical trials for the treatment of relapsed/refractory multiple myeloma: O-12-M1, Horizon, Ocean, Anchor and Bridge. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.   Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to…

Ron Peck, MD, CMO of Arvinas @Arvinas on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as drugs. Degradation of proteins has a major therapeutic promise: PROTAC protein degraders can remove almost all of a…

Ron Peck, MD, CMO of Arvinas @Arvinas answers common questions on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as drugs. Degradation of proteins has a major therapeutic promise: PROTAC protein degraders can remove almost…

Ron Peck, MD, CMO of Arvinas @Arvinas discusses the initial safety and PK data on an orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as drugs. Degradation of proteins has a major therapeutic promise: PROTAC protein…

Ron Peck, MD, CMO of Arvinas @Arvinas discusses an orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer. Dr. Peck further explains the approach to targeted protein degradation and why it might have potential in oncology. The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious. The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as…

Dr. Mark Tuthill, MD of University of Oxford explains the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy and the key steps to phase 3. _____________ Vaccitech Limited and Oxford University today revealed initial efficacy and safety results for ADVANCE, a Phase 2a research testing VTP-800, a candidate for immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that the VTP-800 is safe and showed an positive trend in efficacy in mCRPC patients. ADVANCE (NCT03815942) is an open-label, non-randomized research sponsored and performed by the University of Oxford, funded by the FP7 and Vaccitech programs…

Dr. Mark Tuthill, MD of University of Oxford answers the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy: are they accepting new patients for the study? _____________ Vaccitech Limited and Oxford University today revealed initial efficacy and safety results for ADVANCE, a Phase 2a research testing VTP-800, a candidate for immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that the VTP-800 is safe and showed an positive trend in efficacy in mCRPC patients. ADVANCE (NCT03815942) is an open-label, non-randomized research sponsored and performed by the University of Oxford, funded by the FP7 and Vaccitech…

Dr. Mark Tuthill, MD of University of Oxford discusses the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy. _____________ Vaccitech Limited and Oxford University today revealed initial efficacy and safety results for ADVANCE, a Phase 2a research testing VTP-800, a candidate for immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that the VTP-800 is safe and showed an positive trend in efficacy in mCRPC patients. ADVANCE (NCT03815942) is an open-label, non-randomized research sponsored and performed by the University of Oxford, funded by the FP7 and Vaccitech programs of the European Commission. The research aims…

Dr. James Bates, MD @JamesBatesMD of University of Florida @UF answers is this reflective of long term techniques on long term outcomes in 10-year survivors of early-stage hodgkin lymphoma. ___________ Although radiation therapy enhances progression-free survival in early-stage Hodgkin lymphoma (HL), significant questions remain about the effect on quality of life and survival of delayed normal tissue impacts. We hypothesized that combined-modality therapy (CMT; chemotherapy and radiation therapy) care increases overall survival among 10-year survivors as opposed to radiation therapy or chemotherapy care alone.

Dr. James Bates, MD @JamesBatesMD of University of Florida @UF discusses long term outcomes in 10-year survivors of early-stage hodgkin lymphoma. ________ Although radiation therapy enhances progression-free survival in early-stage Hodgkin lymphoma (HL), significant questions remain about the effect on quality of life and survival of delayed normal tissue impacts. We hypothesized that combined-modality therapy (CMT; chemotherapy and radiation therapy) care increases overall survival among 10-year survivors as opposed to radiation therapy or chemotherapy care alone.

Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small cell lung cancer. ______________ ALUNBRIG’s Phase 3 ALTA-1L (ALK in BrigAtinib’s Lung Cancer Trial in 1st line) study in adults is a global, ongoing, randomized, open-label, comparative, multicenter study that enrolled 275 patients (ALUNBRIG, n=137, crizotinib, n=138) with ALK+ locally advanced or metastatic NSCLC who did not receive an ALK inhibitor prior care. Patients received either ALUNBRIG, 180 mg once daily at 90 mg once daily with seven-day lead-in, or crizotinib, 250 mg twice daily. In the ALUNBRIG arm the…

Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small cell lung cancer. What is Intracranial Efficacy in ALUNBRIG for ALK + NSCLC? ______________ ALUNBRIG’s Phase 3 ALTA-1L (ALK in BrigAtinib’s Lung Cancer Trial in 1st line) study in adults is a global, ongoing, randomized, open-label, comparative, multicenter study that enrolled 275 patients (ALUNBRIG, n=137, crizotinib, n=138) with ALK+ locally advanced or metastatic NSCLC who did not receive an ALK inhibitor prior care. Patients received either ALUNBRIG, 180 mg once daily at 90 mg once daily with seven-day lead-in, or…

Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small cell lung cancer. ______________ ALUNBRIG’s Phase 3 ALTA-1L (ALK in BrigAtinib’s Lung Cancer Trial in 1st line) study in adults is a global, ongoing, randomized, open-label, comparative, multicenter study that enrolled 275 patients (ALUNBRIG, n=137, crizotinib, n=138) with ALK+ locally advanced or metastatic NSCLC who did not receive an ALK inhibitor prior care. Patients received either ALUNBRIG, 180 mg once daily at 90 mg once daily with seven-day lead-in, or crizotinib, 250 mg twice daily. In the ALUNBRIG arm the…

Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia. _____________ INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported promising interim results from an open-label, Phase 2 study showing its lead DNA candidate VGX-3100 to be safe and successful in treating men and women with anal dysplasia, also known as high-grade squamous intraepithelial lesion (HSIL), a precancerous disease caused by high-risk human papillomavirus (HPV) forms 16/18. Of the 20 subjects that had findings at the time of data analysis, 50 percent (10 out of 20 subjects) showed clearance of precancerous lesions…

Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia. _____________ INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported promising interim results from an open-label, Phase 2 study showing its lead DNA candidate VGX-3100 to be safe and successful in treating men and women with anal dysplasia, also known as high-grade squamous intraepithelial lesion (HSIL), a precancerous disease caused by high-risk human papillomavirus (HPV) forms 16/18. Of the 20 subjects that had findings at the time of data analysis, 50 percent (10 out of 20 subjects) showed clearance of precancerous lesions…

Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia. _____________ INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported promising interim results from an open-label, Phase 2 study showing its lead DNA candidate VGX-3100 to be safe and successful in treating men and women with anal dysplasia, also known as high-grade squamous intraepithelial lesion (HSIL), a precancerous disease caused by high-risk human papillomavirus (HPV) forms 16/18. Of the 20 subjects that had findings at the time of data analysis, 50 percent (10 out of 20 subjects) showed clearance of precancerous lesions…

John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed refractory (R/R) chronic lymphocytic leukemia (CLL): how this affects clinicians and what is to come.   venetoclax-rituximab, VenR, chronic lymphocytic leukemia, CLL, murano study

Philadelphia, PA (April 7, 2020) – Oncoceutics, Inc., a clinical-stage drug discovery and development company with a novel class of compounds called imipridones, announced today that Wolfgang Oster, MD, PhD, one the company’s co-founders and Chief Executive Officer, has left the company effective April 3 as part of a leadership change.  He has also left the company’s Board of Directors. Raymond Wong, a director associated with the company’s lead investor, Spring Mountain Capital, is now the company’s Chairman. Lee Schalop, MD, the company’s Chief Operating Officer, is now Chief Executive Officer. Martin Stogniew, PhD, remains the company’s Chief Development Officer. Josh…

Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews explains the phase II trial in effective immunotherapy with markers of immune activation in metastatic prostate cancer.  While metastatic castration-resistant prostate cancer (mCRPC) usually has minimal response to immunotherapy, in a Phase II trial at The University of Texas MD Anderson Cancer Center, a subset of patients with pretreatment evidence of active T-cell responses in their tumors observed sustained survival following treatment with ipilimumab. “Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,” said lead author Sumit Subudhi, M.D., Ph.D.,…

Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews answers if the markers are predictive of outcomes on immunotherapy with markers of immune activation in metastatic prostate cancer. While metastatic castration-resistant prostate cancer (mCRPC) usually has minimal response to immunotherapy, in a Phase II trial at The University of Texas MD Anderson Cancer Center, a subset of patients with pretreatment evidence of active T-cell responses in their tumors observed sustained survival following treatment with ipilimumab. “Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,” said lead author Sumit Subudhi,…

Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews discusses effective immunotherapy with markers of immune activation in metastatic prostate cancer. While metastatic castration-resistant prostate cancer (mCRPC) usually has minimal response to immunotherapy, in a Phase II trial at The University of Texas MD Anderson Cancer Center, a subset of patients with pretreatment evidence of active T-cell responses in their tumors observed sustained survival following treatment with ipilimumab. “Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,” said lead author Sumit Subudhi, M.D., Ph.D., assistant professor of Genitourinary Medical Oncology.…

David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai: how information is generated. A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI FOLFOXaiTM, the latest addition to the company’s extensive molecular science portfolio. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of FOLFOX chemotherapy response in metastatic colorectal cancer that showed an increase of approximately 50 percent in overall survival through two independent validation studies. Using the findings of Caris Molecular Intelligence ® tumor profiling, this AI-powered predictor is designed to gage the probability of a…

David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai. A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI FOLFOXaiTM, the latest addition to the company’s extensive molecular science portfolio. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of FOLFOX chemotherapy response in metastatic colorectal cancer that showed an increase of approximately 50 percent in overall survival through two independent validation studies. Using the findings of Caris Molecular Intelligence ® tumor profiling, this AI-powered predictor is designed to gage the probability of a patient benefiting from FOLFOX…

A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI FOLFOXaiTM, the latest addition to the company’s extensive molecular science portfolio. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of FOLFOX chemotherapy response in metastatic colorectal cancer that showed an increase of approximately 50 percent in overall survival through two independent validation studies. Using the findings of Caris Molecular Intelligence ® tumor profiling, this AI-powered predictor is designed to gage the probability of a patient benefiting from FOLFOX in combination with bevacizumab as a first-line regimen. Two separate data sets…

Dr. Giuseppe Curigliano, MD, PhD @curijoey of University of Milan on patient care and COVID-19 containment in Italy. Read here: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200068/full/?cid=DM4782&bid=40579286

Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth discusses the patients with newly diagnosed glioblastoma, initial experience with scalp saving radiation using combined temozolomide and tumor treatment fields (SPARE). Glioblastoma care quality involves concomitant chemoradiation and temozolomide management with tumor treatment fields (TTF fields). Preclinical studies indicate synergistic effects of TTF fields, and radiation therapy. We record our initial experience evaluating scalp-sparing radiation toxicity and tolerability with concurrent TTFields. This is a pilot test with one arm (Clinicaltrials.gov Identifier: NCT03477110). Adult patients (age from 18 years) with KPS from 60 years of age were eligible for newly diagnosed glioblastoma. All…

Dr. Adil Akhtar, MD of Karmanos Cancer Institute discusses important points to note on the rapidly changing COVID-19 for cancer patients and treatment. Early reports concerning cancer patients from Wuhan, China — the initial COVID-19 pandemic epicenter — indicate that many have contracted the coronavirus while in hospital care. That may mean that this vulnerable group may need to consider delaying treatment for cancer to help reduce their chances of infection.  Read here: https://www.webmd.com/lung/news/20200325/covid-19-may-delay-some-cancer-treatments#1

Dr. Adil Akhtar, MD of Karmanos Cancer Institute discusses COVID-19 possibly delaying cancer treatments because during treatment, patients may be exposed to the coronavirus. Early reports concerning cancer patients from Wuhan, China — the initial COVID-19 pandemic epicenter — indicate that many have contracted the coronavirus while in hospital care. That may mean that this vulnerable group may need to consider delaying treatment for cancer to help reduce their chances of infection.  Read here: https://www.webmd.com/lung/news/20200325/covid-19-may-delay-some-cancer-treatments#1

Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth answers common questions asked on the patients with newly diagnosed glioblastoma, initial experience with scalp saving radiation using combined temozolomide and tumor treatment fields (SPARE).  Glioblastoma care quality involves concomitant chemoradiation and temozolomide management with tumor treatment fields (TTF fields). Preclinical studies indicate synergistic effects of TTF fields, and radiation therapy. We record our initial experience evaluating scalp-sparing radiation toxicity and tolerability with concurrent TTFields. This is a pilot test with one arm (Clinicaltrials.gov Identifier: NCT03477110). Adult patients (age from 18 years) with KPS from 60 years of age were eligible for…

What is KEYNOTE-189? Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses important points to note in NSCLC. In KEYNOTE-189, first- pembrolizumab plus pemetrexed- significantly improved overall survival (OS) and progression- survival (PFS) compared to placebo plus pemetrexed- in patients with non– non- metastatic lung cancer (NSCLC), regardless of the expression of tumor programmed death- 1 (PD-). Patients were allocated randomly (2:1) to receive pemetrexed and platinum plus pembrolizumab (n=410) or placebo (n=206) for 4 cycles every 3 weeks, then pemetrexed maintenance plus pembrolizumab or placebo for up to 35 cycles in total. In the placebo-combination category, eligible patients…

Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer answers common questions on KEYNOTE-189. If the PD-L1 expression is less than 1%, should therapy for pembrolizumab be considered in NSCLC? In KEYNOTE-189, first- pembrolizumab plus pemetrexed- significantly improved overall survival (OS) and progression- survival (PFS) compared to placebo plus pemetrexed- in patients with non– non- metastatic lung cancer (NSCLC), regardless of the expression of tumor programmed death- 1 (PD-). Patients were allocated randomly (2:1) to receive pemetrexed and platinum plus pembrolizumab (n=410) or placebo (n=206) for 4 cycles every 3 weeks, then pemetrexed maintenance plus pembrolizumab or placebo for up…

Philadelphia, PA (April 1, 2020) – Oncoceutics, Inc., announced that it was informed by its Japanese licensee, Ohara Pharmaceutical Co., Ltd., of the initiation of a Phase I/II clinical study of OP-10 (the Japanese name for ONC201) in Japan and the administration of the drug to the first patient.  ONC201 is a novel small molecule with a unique mechanism of action that has demonstrated anti-cancer activity and safety in preclinical models and in several ongoing clinical trials, including clinical trials in adult and pediatric patients with high-grade glioma. In February 2019, Oncoceutics outlicensed rights to ONC201 for Japan to Ohara. Under…

Philadelphia, PA (March 26, 2020) – Oncoceutics, Inc. announced that the Chinese National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a Composition of Matter patent for ONC201, the company’s lead development candidate, as well as for several other compounds of the imipridone family.  This new patent, along with a Composition of Matter patent for ONC201 issued in the United States in March 2019 and an intention to grant from the European Patent Office issued in August 2019, gives Oncoceutics extensive coverage for ONC201 around the world.  Oncoceutics licensed this group of patents from The Scripps Research Institute…

Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses an updated analysis on KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for untreated metastatic NSCLC. In KEYNOTE-189, first- pembrolizumab plus pemetrexed- significantly improved overall survival (OS) and progression- survival (PFS) compared to placebo plus pemetrexed- in patients with non– non- metastatic lung cancer (NSCLC), regardless of the expression of tumor programmed death- 1 (PD-). Patients were allocated randomly (2:1) to receive pemetrexed and platinum plus pembrolizumab (n=410) or placebo (n=206) for 4 cycles every 3 weeks, then pemetrexed maintenance plus pembrolizumab or placebo for up to 35 cycles in…

Amy Moore, PhD @amoorephd of GO2 Foundation of Lung Cancer @GO2Foundation explains that COVID-19 infection rate is doubled for cancer patients. The coronavirus disease, called COVID-19, is in the minds of many people at the front and centre. For so many this is troubling, particularly for cancer patients and their families. Now declared by the World Health Organization (WHO) as a pandemic, the majority of people who develop COVID-19 experience only mild symptoms, including colds. WHO says that 80 percent of COVID-19 people are recovering without needing any specialist care. According to the CDC, some groups, including elderly adults and…

Heinz-Josef Lenz, MD Professor of Medicine and Preventive Medicine Associate Director, Clinical Sciences J Terrence Lanni Chair in Cancer Research Director, USC Center for Molecular Pathways and Drug Discovery USC / Norris Comprehensive Cancer Center outlines an Update on Molecular Targeted Therapies for Metastatic colorectal cancers including in depth conversation on Next-generation sequencing, The Colorectal Cancer Subtyping Consortium, bevacizumab, EGFR, 80405 trial, Gerlinger et al., NEJM 2012, Circos plot illustrating genome-wide CNA, Liquid Biopsies, KRAS, MGH GI, RAS-WT CRC, ctDNA, CALGB, SWOG 80405, Cetuximab, FOLFIRI, FOLFOXIRI, CRICKET Trial, PD-1 Blockade, Nivolumab Monotherapy, BRAF, HER2 Overexpression,Trastuzumab,HER2, ZW25, DS-8201a, BEACON CRC Phase…

Amy Moore, PhD @amoorephd of GO2 Foundation of Lung Cancer @GO2Foundation discusses the intersection of COVID-19 and lung cancer patients. The coronavirus disease, called COVID-19, is in the minds of many people at the front and centre. For so many this is troubling, particularly for cancer patients and their families. Now declared by the World Health Organization (WHO) as a pandemic, the majority of people who develop COVID-19 experience only mild symptoms, including colds. WHO says that 80 percent of COVID-19 people are recovering without needing any specialist care. According to the CDC, some groups, including elderly adults and people…

Tanya Dorff, MD Associate Clinical Professor of MedicineHead of Genitourinary Cancer Program City of Hope discusses Genitourinary Cancers:Evolving Practices and Controversies, STAMPEDE: (Docetaxel) in mHSPC, LATITUDE Trial, docetaxel, ENZAMET, SWOG S1802, TITAN, mCRPC, Cabazitaxel, Enzalutamide, Radium223, Sipuleucel-T, Docetaxel (TAX), ADT, A031201, EORTC 1333 / PEACE III2, PARP inhibitors, TOPARP- B, niraparib, rucaparib, talazoparib, PHASE III PROFOUND, Pembrolizumab, KEYNOTE-991, 177-Lu PSMA, VISION trial, CAR-T, BiTE antibody, Erdafitinib, FGFR TKI, Enfortumab, EV 302, Docetaxel, Vofatamab, nivoluamb and more at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology …

Zev A. Wainberg, MD Associate Professor Of Medicine Co-Director GI Oncology Program David Geffen School of Medicine at UCLA gives an update in Gastrointestinal Cancers including KEYNOTE-059, Pembrolizumab, MSI-H KN 059, MSI-H KN 059 061, KEYNOTE 181, KEYNOTE-062, KEYNOTE 59, KEYNOTE-811, CHECKMATE-649, Javelin Gastric 100, SPOTLIGHT (FAST-2) 1L Claudin+, FIGHT 1L FGFR2, PRODIGE 24/CCTG PA.6 trial at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology  Puma Biotechnology  Tempus  Verastem oncology Walgreens 

Nick McAndrew, MD MSCE Clinical Instructor Division of Hematology / Oncology UCLA David Geffen School of Medicine discusses updates in Breast CancerSummary of 2019 practice changing studies Overall Survival UpdatesCDK 4/6 Inhibitors: MONALEESA 3, 7 and MONARCH 2, Adjuvant Pertuzumab: APHINITY, ER+, First PI3K Inhibitor Approval: SOLAR-1, HER2+, Tyrosine Kinase Inhibitors: NALA, HER2CLIMB, New ADC: DESTINY-Breast01Triple Negative, Checkpoint Inhibitor in mBC: IMpassion130 Neoadjuvant Checkpoint Inhibitors: KEYNOTE-522, NeoTRIP at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology  Puma Biotechnology  Tempus  Verastem oncology Walgreens 

Herbert Eradat, MD, MS @dgsomucla Associate Clinical Professor UCLE Lymphoma Program UCLA BMT & CAR-T Cell Program, David Geffen School of Medicine UCLA discusses An Update on Diffuse Large B-Cell Lymphoma Novel Therapeutic Strategies at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology  Puma Biotechnology  Tempus  Verastem oncology Walgreens 

Nagi El Saghir, MD @NagiSaghir of American University of Beirut Medical Center @AUBMC_Official discusses how to care for oncology patients and being educated during the current COVID-19 pandemic. As with the majority of the world’s population, hematologists, oncologists and their patients are now on the alert to face the COVID-19 pandemic worldwide. Indeed we are among the most worried as our patients might be more vulnerable. Owing to regular routine visits to clinics and hospitals, our patients are at higher risk of contracting the virus and, if they acquire COVID-19, they are at higher risk of severe complications and mortality…

Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA answers common questions on the characteristics and trends in adult acute lymphoblastic leukemia. There is still a survival benefit for patients who are referred, even if they do not undergo transplant, because of therapy and clinical trials. ______________ It is difficult to treat acute lymphoblastic leukemia (ALL) in a socioeconomic distressed community without ready access to a center for hematopoietic stem cell transplantation (HCT), and clinical trials. Sparse data concerning the outcomes of these patients. This retrospective study included 90 consecutive ALL patients, who presented between 2003 and 2018 to Harbor-UCLA.…

Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA discusses the characteristics and trends in adult acute lymphoblastic leukemia. The primary objective was overall survival. Secondary objectives included leukemia-free survival, toxicities of therapy, and referral for HCT and incidence of successful HCT. ALL in a vulnerable population without access to an HCT center is challenging. ______________ It is difficult to treat acute lymphoblastic leukemia (ALL) in a socioeconomic distressed community without ready access to a center for hematopoietic stem cell transplantation (HCT), and clinical trials. Sparse data concerning the outcomes of these patients. This retrospective study included 90 consecutive ALL…